Bionomics to Launch Anti-Cancer Drug Trial in Australia

8 December 2009 (Last Updated December 8th, 2009 18:30)

Bionomics will carry out a Phase II clinical trial of its BNC105 anti-cancer drug on mesothelioma patients across Australia. Mesothelioma is a cancer usually associated with asbestos that allows malignant cells to develop around the body's internal organs. Bionomics announced

Bionomics will carry out a Phase II clinical trial of its BNC105 anti-cancer drug on mesothelioma patients across Australia.

Mesothelioma is a cancer usually associated with asbestos that allows malignant cells to develop around the body’s internal organs.

Bionomics announced a Phase II clinical trial of BNC105 in the US for renal cancer earlier this year.

The Australian trial will be carried out on 60 patients at up to 12 centres, according to smh.com.au.